On October 9, 2024, Circle Pharma (Circle), a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, and Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced a new research collaboration and licensing agreement with a shared objective to create a pioneering cyclin inhibitor. This innovative development could potentially halt the growth of cancer cells in patients living with hard-to-treat cancers. Wilson Sonsini advised Circle on the transaction.

The collaboration will expand Boehringer Ingelheim’s oncology portfolio and support its target to transform cancer care. In connection with the agreement, Circle will receive an upfront payment and potential development, regulatory, and sales milestone payments worth up to $607 million.

The Wilson Sonsini team that advised Circle on the transaction includes Alex Key, Miruna Predescu, and Rachel Slyker.

For more information, please see Boehringer Ingelheim's and Circle's joint news release. Additional coverage can be found on Fierce Biotech.